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Abstract
Background: VirtUaL ChIP-seq Analysis through Networks (VULCAN) infers regulatory interactions of transcription
factors by overlaying networks generated from publicly available tumor expression data onto ChIP-seq data. We
apply our method to dissect the regulation of estrogen receptor-alpha activation in breast cancer to identify
potential co-regulators of the estrogen receptor’s transcriptional response.
Results: VULCAN analysis of estrogen receptor activation in breast cancer highlights the key components of the
estrogen receptor complex alongside a novel interaction with GRHL2. We demonstrate that GRHL2 is recruited to a
subset of estrogen receptor binding sites and regulates transcriptional output, as evidenced by changes in estrogen
receptor-associated eRNA expression and stronger estrogen receptor binding at active enhancers after GRHL2
knockdown.
Conclusions: Our findings provide new insight into the role of GRHL2 in regulating eRNA transcription as part of
estrogen receptor signaling. These results demonstrate VULCAN, available from Bioconductor, as a powerful
predictive tool.
Keywords: Breast cancer, Network analysis, Dynamics, ER, Master regulator, ChIP-seq, VULCAN, GRHL2, P300,
H3K27ac
Introduction
Breast cancer is the most common form of cancer in
women in North America and Europe accounting for
31% of all new cancer cases. In the USA, it is estimated
that 41,400 deaths will have occurred from the disease
in 2018 [1]. The majority of breast cancers, approxi-
mately 70%, are associated with deregulated signaling by
the estrogen receptor-alpha (ER), which drives tumor
growth. Therefore, in ER-positive (ER+) tumors, ER is
the primary therapeutic target. During activation, ER
recruits several cofactors to form an active complex on
the chromatin. FOXA1 is of particular interest as the
protein shares nearly 50% of its genomic binding sites
with ER and has been shown to operate as a pioneer
factor before ER activation [2, 3]. It is through FOXA1
and other cofactors (e.g., SRC-1) [4, 5] that ER is able
to recruit RNA polymerase II at the gene promoter
sites by way of adaptor proteins in order to initiate
transcription [6]. Combinatorial treatments targeting
ER cofactors present a significant opportunity in breast
cancer therapy for increasing patient survival. In
particular, the pioneer factor FOXA1 [7] has been
identified as a novel therapeutic target for the treat-
ment of breast cancer, while the EZH2-ERα-GREB1
transcriptional axis has been shown to play a key role
in therapeutic resistance [8].
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ChIP-seq enables the identification of potential
site-specific interactions at common binding sites be-
tween transcription factors and their cofactors; however,
to fully characterize all potential cofactors of a single
project on this scale is laborious and expensive. To fol-
low up all potential cofactors identified by a
chromatin-wide proteomics method, e.g., RIME [9] or
ChIP-MS [10], would take hundreds of individual
ChIP-seq experiments. Studies like ENCODE [11] have
gone a long way to provide resources to meet these chal-
lenges; however, the inherent scale of the problem
means public studies can only offer data for a subset of
TF in a limited number of models. A single lab to under-
take this level of experimentation is unfeasible and, in
cases where suitable antibodies for the ChIP do not
exist, impossible.
To enable discoveries beyond collections like EN-
CODE, we are proposing a computational framework to
integrate patient data in the prediction of functional
protein-protein interactions. By applying machine learn-
ing methods, we are able to surpass the limitation of
current predictive tools that exist to support the inter-
pretation of data. Previous methods provide information
in the context of predefined biological pathways and
established gene sets [12, 13] or through motif analysis
[14], while our method is built on data specific to the
disease being studied. Further, standard gene set enrich-
ment analysis has inherent limitations because it was
not designed for reconstructing gene networks, whereas
one of the advantages of VULCAN is that it down
weights genes shared by multiple TFs.
Our method, “VirtUaL ChIP-seq Analysis through
Networks” (VULCAN), is able to specifically analyze the
potential disease-specific interactions of TFs in ChIP-seq
experiments by combining machine learning approaches
and patient data. Previously, the strategies employed by
VULCAN were limited to the analysis of transcription
data. By developing VULCAN to overlay co-expression
networks established from patient tumor data onto
ChIP-seq data, we are able to provide candidate
co-regulators of the response to a given stimulus (Fig. 1).
Further, as VULCAN builds on transcriptional master
regulator analysis, the output from the pipeline provides
the end user with functional information in terms of the
activity of potentially interacting TFs. The combination
of disease-specific context and TF activity information
presents a significant step forward in providing valuable
information for the elucidation of on-chromatin interac-
tions from ChIP-seq experiments over previous
strategies.
Through the application of VULCAN to the activation
of the ER in breast cancer, we were able to identify mul-
tiple previously characterized cofactors of the ER along
with GRHL2 as a potential co-repressor of the ER. We
then demonstrated experimentally that GRHL2 is able to
modulate the expression of eRNA at ER bound en-
hancers, and the removal of the P300 inhibitory alpha
helix results in suppression of the inhibitory effect on
eRNA production.
Results
VULCAN integrates ChIP-seq data (Fig. 1, step 1) with
co-expression networks (Fig. 1, step 2) to predict cofac-
tor activity (Fig. 1, step 3). The initial ChIP-seq data is
converted into genomic regions, and if multiple condi-
tions are supplied, the changes in the transcription fac-
tor affinity are calculated. In parallel, master regulator
analysis of tumor transcriptional data is used to provide
tissue-specific information on the regulation of genes by
TFs within the tumor type. The integration of these two
data types provides context-specific results and differen-
tiates VULCAN from the existing methods which make
Fig. 1 An overview of VULCAN. (1) ChIP-seq analysis from multiple conditions is undertaken to generate cistrome data at multiple time points (or
conditions). Binding events are then compared using differential binding analysis to establish log-fold change values for individual binding events
between each time point. (2) Network generation was undertaken with ARACNe-AP by inferring all pairwise TF-target co-expression from patient
datasets (e.g., TCGA breast and METABRIC datasets). (3) All the targets of each specific TF in the network, i.e., the individual regulons, are tested
against the established changes in ER binding through the msVIPER algorithm [15] to identify proteins that interact with the target transcriptional
factor and final prediction is given for potential interacting cofactors
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use of predefined unweighted gene sets or motif analysis.
VULCAN additionally makes use of the key functionality
of the VIPER algorithm [15] that assigns edge-specific
scores like mode of action and likelihood to the recon-
structed network.
In the following, we first benchmark VULCAN’s per-
formance in a comprehensive comparison to alternative
approaches. We then apply it to our data on temporal
ER binding, which identifies GRHL2 as a novel ER co-
factor, and we explore its function.
Comparison of VULCAN to existing methods
Mutual information networks outperform partial correlation
networks
We generated a mutual information network with AR-
CANe alongside several partial correlation networks at
different thresholds all from the TCGA breast cancer
data. To ensure the robustness of our method, we tested
the overlap of every partial correlation network with the
mutual information network using the Jaccard index (JI)
criterion (Additional file 1: Figure S1). Finally, we
showed how the Jaccard index between partial correl-
ation networks and the ARACNe network is always sig-
nificantly higher than expected by selecting random
network edges (Additional file 1: Figure S2). For further
analysis, we selected the mutual information network
generated by ARACNe as this method outperformed the
partial correlation networks at all thresholds.
GSEA is the optimum method for VULCAN’s target
enrichment analysis
VULCAN applies gene set enrichment analysis [16] to
identify enrichment of our mutual information network
derived regulons in differential ChIP-seq data. To
validate our method, we compared the results of
VULCAN when applied to our ER binding data against
three independent methods previously applied to
benchmark VIPER [15]. First, we implemented a Fisher
p value integration step. This test lacks stringency and
results in nearly all regulons as significantly enriched
(Additional file 1: Figure S3). Second, we implemented a
fraction of targets method, defining for every TF the
fraction of their targets that are also differentially bound.
This alternative to VULCAN ignores the MI strength of
interaction and the individual strengths of differential
bindings, reducing the resolving power of the algorithm
(Additional file 1: Figure S4). Finally, we compared to
Fisher’s exact method, which assesses the overlap be-
tween networks and significant differential binding. This
method is too stringent (as observed in the original
VIPER paper) [15]; and even without p value correction,
there are no significant results, even at low stringency,
demonstrating the low sensitivity of using Fisher’s exact
method (Additional file 1: Figure S5). In summary,
VULCAN GSEA implementation outperformed all three
alternative methods we tested (t test based; fraction of
targets method; and Fisher’s exact method) in our data-
set and was therefore applied to all downstream analysis
of ChIP-seq data.
VULCAN outperforms enrichment analysis tools (GREAT,
ISMARA, and ChIP-Enrich)
To further validate our method, we compared the out-
put of our GSEA analysis with different versions of
promoter-enrichment approaches implemented by
GREAT [12], ISMARA [14], and ChIP-Enrich [13]. The
VULCAN analysis shows a significant overlap in terms
of detected pathways with the GREAT method
(Additional file 1: Figure S6). ChIP-Enrich identifies
enrichment of a number of TFs also predicted by
VULCAN, but it fails to identify ESR1 as the top
transcription factor affected by our experiment
(Additional file 1: Figure S7). ISMARA succeeds at iden-
tifying ESR1 using a motif-based analysis but does not
identify other candidate binding TFs (Additional file 1:
Figure S8). In summary, VULCAN outperforms both
ISMARA and ChIP-Enrich, and significantly overlaps
with GREAT, but provides additional value through
inference of TF factor activity.
Temporal analysis of ER DNA binding profiles after
activation by E2
We performed four replicated ChIP-seq experiments for
ER at three time points (0, 45, and 90min) after estra-
diol treatment (Fig. 2) in the ER+ breast cancer cell line,
MCF7. The cistromic profile of ER at 45 and 90min was
then compared to 0 min to identify binding events
enriched by E2. Our analysis (Fig. 2b, c) identified
18,900 statistically significant binding events at 45 min
(FDR < 0.05) and 17,896 numbers at 90 min. We vali-
dated the ER binding behavior with ChIP-qPCR (Fig. 2a),
and the response was sustained, in agreement with our
previous study [17].
We performed motif enrichment analysis (HOMER
software) on ER binding sites detected by differential
binding analysis. Our analysis confirmed a strong enrich-
ment for a single element, ERE, bound at both 45 and
90min, with a corrected p value of 0.0029 (Fig. 3f ).
When clustered according to peak intensity, the samples
cluster tightly in two groups: treated and untreated
(Additional file 1: Figures S9, S10, and S11), but treat-
ment at 45 and 90min is detectably different on a
genome-wide scale, as highlighted by principal compo-
nent analysis (Additional file 1: Figure S12 and S13).
We performed a gene set enrichment analysis (GSEA)
[16] and an associated rank enrichment analysis (aREA)
[15] using the differential binding at gene regulatory re-
gions with time 0 as reference. Individual differential
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Fig. 2 Dynamic behavior during early activation of ER. ChIP-qPCR of the TFF1 gene (a) at three time points shows increased binding of ER at 45
min after MCF7 cells are stimulated by estradiol. The previously reported maximum is followed by a decrease in the TFF1 promoter occupancy at
90 min. p values are generated by one-tailed t test. The maximal point at 90 min was identified as an outlier (> median + 2 × IQR); however, the
removal did not alter the significance of results. (b) Differential binding analysis of ChIP-seq data at three time points to monitor the activation of
ER. The ER exhibits a strong increase in binding at 45 min vs 0 min (c), and the majority of sites still display binding at 90min
Fig. 3 ER occupancy after estradiol treatment in terms of TF network activity. (a) Global TF network behavior as predicted by VULCAN in our
ChIP-seq dataset, highlighting the ESR1 TF at time 0 and 45/90min after estradiol treatment. (b) Global TF activity after estradiol treatment in
MCF7 cells, inferred using the METABRIC network, highlighting TFs significantly upregulated at 45min and 90 min. (c) Global TF activity after
estradiol treatment in MCF7 cells, inferred using the METABRIC network, highlighting TFs significantly downregulated at 45 min and 90min. (d)
Global TF activity after estradiol treatment in MCF7 cells, inferred using the METABRIC network, highlighting TFs significantly upregulated at 45
min but not at 90min. (e) Global TF activity after estradiol treatment in MCF7 cells, inferred using the METABRIC network, highlighting TFs significantly
upregulated at 90min but not at 45min. (f) Most enriched motif in peaks upregulated at both 45 and 90min after estradiol treatment, as predicted
by HOMER
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binding signatures for GSEA were calculated using a
negative binomial test implemented by DiffBind [18].
The collective contribution of differentially bound sites
highlights several ER-related pathways in both the GSEA
and aREA analyses [19–21] (Additional file 1: Figure
S14). The strongest upregulated GSEA pathway in both
time points (Additional file 1: Tables S1 and S2) was de-
rived from RNA-seq in an MCF7 study using estradiol
treatment [20], confirming the reproducibility of our
dataset.
VULCAN analysis of ER activation
VULCAN identifies coactivators and co-repressors of ER
We leveraged the information contained in mutual in-
formation networks to establish TF networks enriched in
the differential binding patterns induced by estradiol.
From our analysis of ER binding, we established four
classes of modulation: early coactivators, early
co-repressors, delayed coactivators, and transient coacti-
vators (Fig. 3).
Using VULCAN, we defined TF network activity of oc-
cupied regulatory regions (Fig. 3a) according to the
binding of ER within their promoter and enhancer re-
gions (limited to 10 kb upstream of the transcription
starting site to ensure gene specificity). We define early
coactivators as those TFs whose network is upregulated
at both 45 and 90min (Fig. 3b); these genes include AR,
SP1, and CITED1. TFs with opposite behavior (namely
TFs whose negative/repressed targets in the ARACNe
model are occupied by ER), or “early co-repressors,” in-
clude GLI4, MYCN, and GRHL2 (Fig. 3c). Some TFs ap-
pear to have their targets transiently bound at 45 min
but then unoccupied at 90 min, and therefore, we
dubbed them “transient coactivators” (Fig. 3d). We fur-
ther defined TFs active at 90 min but not at 45 min as
“delayed coactivators,” noting these cofactors could be
the transient if the response is not completed by 90 min.
While this category exists, and notably contains both
ESR1 and the known ESR1 interactor GATA3, it is just
below the significance threshold at 45 min (Fig. 3e).
We repeated our TF network activity analysis of ER
activation (Fig. 3a–e) on an independent dataset from
TCGA and found similar results to those established
from the METABRIC-derived network (Additional file 1:
Figures S14, S15, S16, S17, S18, and S19).
To ensure the robustness of the results, we performed
a joint analysis of data obtained from both networks. At
45 (Fig. 4a) and 90 min (Fig. 4b), we identified candi-
dates, specifically the ESR1, GATA3, and RARA net-
works, which were consistently and robustly activated by
ER in both time points. The joint analysis also identified
candidate co-repressors, including HSF1 and GRHL2.
VULCAN results are specific to the tissue used for network
modeling
Regulatory networks can be tissue specific due to a variety
of biological reasons, such as chromatin status, cofactor
availability, and lineage-dependent transcriptional rewiring
[15]. We tested whether our VULCAN results can be af-
fected by the choice of the ARACNe-inferred regulatory
network. In order to do so, we required a gene expression
dataset large enough for robust mutual information infer-
ence (> 100 samples), based on the same library prepar-
ation and sequencing protocols as the breast cancer
TCGA dataset used in our analysis (to remove the possi-
bility of technical differences), but ultimately derived from
Fig. 4 Global TF activity after estradiol treatment using different network models. XY scatter showing the TF activity as calculated by VULCAN for
our differential ChIP-seq analysis of ER binding at 45min (a) and at 90min (b) after stimulation with 100 nM E2. Comparison of the results calculated
using the METABRIC (y-axis) and TCGA (x-axis) networks shows consistent results know ER interactors including PGR, RARA, GATA3, and GRHL2. GRHL2
activity is notably enriched against. The regulon of ER is also consistently enriched in both networks. Pearson’s correlation coefficient (PCC) shown
along with the significance
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a tissue as distant as possible from breast cancer (BRCA)
on which network models on this study are derived. For
this purpose, we computed ARACNe regulatory models on
the TCGA dataset for acute myeloid leukemia (AML), a li-
quid tumor histologically very different from BRCA. This
AML-derived network shows globally weaker VULCAN
enrichment scores than the BRCA-derived network and a
weak positive correlation with the results obtained through
breast cancer regulatory models (Additional file 1: Figure
S20). The positive correlation suggests that regulatory net-
works inferred in breast cancer are tissue specific and can
only in part be recapitulated by a leukemia-inferred
network.
VULCAN is able to predict protein-protein interactions in
both patient-derived xenografts (PDX) and prostate cancer
To demonstrate the general applicability of VULCAN, we
applied the algorithm to a breast cancer patient-derived
xenograft dataset (Gene Expression Omnibus series
GSE110824) [22, 23], which showed the expected
enrichment of the ESR1, FOXA1, and GATA3 regulons
(Additional file 1: Figure S21 and Fig. 5a) predicting the
co-localization of the respective proteins on the chroma-
tin. To further test the generality of VULCAN, we applied
the method to another cancer-associated transcription fac-
tor type. More specifically, we evaluated an androgen re-
ceptor ChIP-seq dataset derived from prostate cancer cell
line model LNCaP-1F5 and VCaP (Gene Expression
Omnibus Series GSE39880, AR + DHT, RU486, or CPA)
[24]. By applying a context-specific network built from the
TCGA prostate cancer dataset, we could predict
functional co-localization of FOXA1 and AR in target
genes’ promoters after dihydrotestosterone (DHT)
treatment in prostate cell lines (Additional file 1: Fig-
ure S22 and Fig. 5b), validating the known role of
FOXA1 in AR-regulated gene transcription in prostate
cancer [25, 26].
VULCAN outperforms classical motif analysis
Finally, we compared VULCAN to a classical motif ana-
lysis by exploiting the MsigDB C3 collection v6.1 [27] of
gene sets, which contain canonical TF-specific binding
motifs in their promoters. Our analysis shows the correl-
ation of VULCAN results for two transcription factors
(e.g., between GATA3 and ESR1, Additional file 1: Figure
S23) can be relatively high but not significantly overlap-
ping in terms of target genes containing the same ca-
nonical motifs (Additional file 1: Figure S24). We could
prove that this non-relationship is general as it extends
to the majority of TF-TF pairs that were present in the
MsigDB database (Additional file 1: Figure S25).
Optimization of VULCAN parameters
The network generation algorithm uses established
methods to optimize the parameters for the RNA-seq in-
put (e.g., ARACNE-AP calculates the edge significance
based on data-specific permutation test). By default,
VULCAN can calculate key settings from the provided
ChIP-seq data (e.g., DNA fragment length). Additionally,
parameter choice is tunable at the wish of the user. The
distance from promoter transcription starting site (TSS)
can be tuned to the specific organism investigated by the
Fig. 5 Inferring TF co-occupancy in public datasets with VULCAN. (a) VULCAN activity scores for a few TFs derived from the ER-targeted ChIP-seq
breast cancer patient-derived xenograft (PDX) dataset GSE110824. The behavior of ESR1, FOXA1, and GATA3 is correlated, while FOXC1 shows an
inversely correlated pattern (blue line). Interestingly, the sample with the lowest Allred score (V0980 U) has the lowest activity and the other luminal
markers. (b) VULCAN activity scores for FOXA1 in ChIP-seq experiments targeting the androgen receptor (AR) in LNCaP-1F5 prostate-derived cells
(dataset GSE39880). The bar plots show the relative VULCAN normalized enrichment score calculated on absolute peak intensities after treating cells
with dihydrotestosterone (DHT) and partial AR modulators cyproterone acetate (CPA) and mifepristone (RU486). FOXA1 network binding is higher in
the presence of the strong AR recruiter DHT. This shows an increased FOXA1/AR promoter co-occupancy in DHT-treated cells, in agreement with the
conclusions of the study that originated the dataset. Two replicates for each treatment were produced and are reported in matching colors
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ChIP-seq experiment. In this manuscript, we used 1000
nt for Homo sapiens, but it can be lowered to 100 nt for
bacterial chromosomes, to assign peaks that act as rep-
resentative for the gene.
GRHL2 is a novel ER cofactor
In our analysis of ER dynamics, the GRHL2 transcription
factor was consistently identified as a key player, using
both the METABRIC and TGCA networks. GRHL2 is a
transcription factor that is important for maintaining
epithelial lineage specificity in multiple tissues [28, 29].
It has previously been predicted to exist in
ER-associated enhancer protein complexes [30], but its
function in the ER signaling axis is unknown. Therefore,
we set out to experimentally validate GRHL2 as an ER
cofactor.
There is only a weak, positive correlation between ESR1
and GRHL2 expression in the TCGA and METABRIC
breast cancer datasets (Additional file 1: Figure S26).
Furthermore, GRHL2 does not change significantly in
different PAM50 subtypes, although it is overexpressed in
malignant tissue. The low correlation between GRHL2
expression and subtype implies that the protein is
controlled by mechanisms such as phosphorylation [31],
subcellular localization, or on-chromatin protein-protein
interactions.
qPLEX-RIME detects a significant increase in the ER-GRHL2
interaction on activation
We undertook a complementary, unbiased, experimental
approach combining RIME [9] with TMT [32], called
qPLEX-RIME [33], to identify interactors of ER within the
ER-chromatin complex. We generated ER qPLEX-RIME
data from MCF7 cells treated with estradiol at both 45 and
90min and compared this to the VULCAN dataset (Add-
itional file 1: Figure S27). We found known ESR1 interac-
tors with both methods, namely HDAC1, NCOA3,
GATA3, and RARA. These interactors have positive enrich-
ment according to VULCAN [15], implying the TF’s regu-
lon is over-represented within the differentially bound
genes. Importantly, qPLEX-RIME identified a significant in-
crease in the protein-protein interaction between ER and
GRHL2 in estrogenic conditions. As GRHL2 has a negative
enrichment score in VULCAN, this implies either the pro-
tein is recruited by ER to sites that are significantly depleted
for GRHL2’s regulon or that GRHL2 is established as hav-
ing a negative correlation to the genes regulated at these
sites, i.e., the protein is a co-repressor of the ER.
To assess the chromatin-association of ER and
GRHL2, we undertook GRHL2 ChIP-seq in the absence
(0 min) or presence (45 min) of E2 (Fig. 6a). VULCAN
analysis of the GRHL2 differential binding showed that
ER was the key interacting transcription factor, using
both the TCGA- and METABRIC-derived networks
(Fig. 6b).
We undertook a comparison of GRHL2 binding with pub-
lic datasets (Fig. 6c). Our analysis showed that GRHL2 sites
that responded to estradiol were enriched for ER binding
sites (in agreement with our qPLEX-RIME data and VUL-
CAN results) and FOXA1 (compatible with either an ER
interaction or the previously reported interaction with
MLL3 [30]). Importantly, the changes in GRHL2 binding
profiles after E2 treatment were not a result of altered
GRHL2 protein levels (Fig. 7). Individual analysis of peaks
shows that classical ER promoter binding sites, e.g., RARa,
were not the target of this redistribution of GRHL2, as these
sites were occupied by GRHL2 before E2 stimulation. Motif
analysis of the sites within increased GRHL2 occupancy
showed enrichment for the full ERE (p value = 1 × 10−179)
and the GRHL2 binding motif (p value = 1 × 10−51) (Fig. 6g).
To establish if the recruitment of GRHL2 was primar-
ily related to a transcriptional function or the previously
described interaction with MLL3, we overlapped our
GRHL2 data with that of published H3K4me1/3 [30]
and P300 [34] cistromes. While H3K4me occupancy was
consistent between conditions, we found P300 binding
to be enriched at the E2-responsive GRHL2 sites.
A more detailed analysis of the GRHL2 overlap with
P300 sites showed the greatest co-occupancy of GRHL2/
P300 sites was when both TFs were stimulated by E2
(Fig. 6d). Moreover, the overlap of GRHL2 peaks with
ER ChIA-PET data [ENCSR000BZZ] showed that the
GRHL2-responsive sites were enriched at enhancers over
promoters (Fig. 6e). These findings suggested that the
GRHL2-ER complex is involved in transcription at ER
enhancer sites.
Validation of the ER-GRHL2 interaction by qPLEX-RIME and
co-IP
qPLEX-RIME [33] analysis of GRHL2 in both the
estrogen-free and estrogenic conditions showed high
levels of transcription-related protein interactors includ-
ing HDAC1 (p value = 6.4 × 10−9), TIF1A (p value =
6.4 × 10−9), PRMT (p value = 6.4 × 10−9), and GTF3C2 (p
value = 4.6 × 10−9). p values given for estrogen-free and
estrogenic conditions were comparable. The only protein
differentially bound to GRHL2 in estrogen-free vs estro-
genic conditions was the ER.
We further validated this interaction by co-IP. Our
analysis robustly found that GRHL2 and ER interact in
both MCF7 and T47D cells (Fig. 7). We further validated
the antibody by siRNA knockdown and saw the dis-
appearance of the GRHL2 band at 24 h.
GRHL2 constrains ER binding and activity
We investigated the transcription of enhancer RNAs at
these sites using publicly available GRO-seq data [35]
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Fig. 6 GRHL2 differential ChIP-seq between 0 and 45min. (a) Activation of the ER with estro-2-diol results in a genome-wide increase in GRHL2
binding. (b) VULCAN analysis of the same data shows a significant enrichment for ESR1 sites in both the context of the METABRIC and TGCA
networks. The regulon for FOXA1 is also not enriched. Inspection of known FOXA1/GRHL2 sites (e.g., RARa promoter) shows GRHL2 already
bound. (c) Overlap of GRHL2 binding with public datasets shows that E2-responsive GRHL2 sites show considerable overlap with ER, FOXA1, and
P300 sites; H3K4Me1 and H3K4Me3 show little enrichment. (d) Analysis of P300 binding showed a greater overlap of GRHL2 ER-responsive sites in
the presence of E2 than in control conditions. (e) Overlap with ER ChIA-PET sites showed enrichment for GRHL2 sites at ER enhancers. (f) Analysis
of Gro-SEQ data (GSE43836) at GRHL2 sites. Blue lines are control samples, pink lines are samples after stimulation with E2. In general, GRHL2 sites
(left) show no change in the levels of transcription on the addition of E2; however, E2-responsive GRHL2 sites (right) show a robust increase in
transcription on the activation of the ER. (g) Motif analysis of differentially bound sites gave the top two results as GRHL2 and ER
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[GSE43836] (Fig. 6f ). At E2-responsive sites, eRNA tran-
scription was strongly increased by E2 stimulation; by
contrast, eRNA transcription was largely independent of
E2 stimulation when the entire GRHL2 cistrome was
considered. Analysis of a second GRO-seq dataset,
GSE45822, corroborated these results (Additional file 1:
Figure S28).
To further explore how GRHL2 regulates ER en-
hancers, we measured eRNA expression at the GREB1
[36, 37], TFF1 [38–40], and XBP1 [41, 42] enhancers
after overexpression of GRHL2. At GREB1 and XBP1,
increased GRHL2 resulted in reduced eRNA transcrip-
tion (Fig. 8) (p < 0.05, paired sample t test). Conversely,
eRNA production at the TFF1, XBP1, and GREB1 en-
hancers was moderately increased 24 h after GRHL2
knockdown (Additional file 1: Figure S29). Combining
the data from all three sites established the effect as sig-
nificant by paired sample rank test (p = 0.04, one-tailed
paired sample, Wilcoxon test). Collectively, these data
demonstrate that GRHL2 constrains specific ER enhan-
cer transcription.
A conserved alpha helix between residues 425 and 437
of GRHL2 has previously been shown to inhibit P300
[43]. We therefore overexpressed GRHL2 Δ425–437, a
previously demonstrated non-p300-inhibitory mutant
[43, 44], in three ER-positive breast cancer cell lines
(MCF7, T47D, and ZR75) and compared levels of eRNA
to those recorded for both an empty vector control and
for the overexpression of the wild-type protein (Fig. 8b).
The results of the wild-type study were concordant to
those of our previous analysis (Fig. 8a), suggesting in
general that overexpression GRHL2 leads to the inhib-
ition of eRNA production at certain ER sites. Import-
antly, in all cases, the removal of aa 425–437 from
GRHL2 led to a reduction in the inhibitory effect caused
by overexpression of the wild-type protein and was
found as significant in five out of nine cases test (p <
0.05, t test, single-tail, paired).
We undertook H3K27ac ChIP-seq after knockdown of
GRHL2 by siRNA for 48 h. In both MCF7 and T47D
cells, we saw a significant change in the acetylation
marks surrounding GREB1, and in MCF7, we saw an in-
crease at both XBP1 and GREB1 promoters and a de-
crease at TFF1 (Fig. 9a). Genome-wide, we saw a
redistribution of H3K27 acetylation in both cell lines
(Fig. 9b). Comparison of the sites altered by GRHL2
knockdown showed a stronger signal for ER binding
(Fig. 9c, right).
Discussion
VirtUaL ChIP-seq Analysis through Networks
VULCAN is valuable for the discovery of transcription
factors acting as co-regulators within chromatin-bound
complexes that would otherwise remain hidden. The
challenge of highlighting the cofactors from a ChIP-seq
experiment lays in the infeasibility of reliable proteomic
characterization of DNA-bound complexes at specific
regions. On the other hand, while RNA-seq is arguably
the most efficient technique to obtain genome-wide
quantitative measurements, any transcriptomic approach
cannot provide a full picture of cellular responses for
stimuli that are provided on a shorter timescale than
mRNA synthesis speed, such as the estradiol administra-
tion described in our study. VULCAN, by combining
RNA-seq-derived networks and ChIP-seq cistrome data,
aims at overcoming the limitations of both. Most not-
ably, our method can work in scenarios where candidate
cofactors do not have a well-characterized binding site
or do not even bind DNA directly.
Through comparative analysis, we have robustly
shown that VULCAN is able to outperform other
readily available methods for the prediction of
on-chromatin interactions of transcription factors.
VULCAN achieves this through the integration of
ChIP-seq and tumor transcriptional data. The inher-
ent limitation of our method therefore is that tumor
transcriptional data must be available in sufficient
quantity to build the underlying network for the ana-
lysis, whereas tools based on predefined networks
have no such limitation. In the majority of cases, this
Fig. 7 Estrogen time course and Co-IP of GRHL2. Analysis by western blot of the GRHL2 showed no changes in the levels of GRHL2 at 45 min, 90
min, or 24 h after stimulation with estradiol in either MCF7 or T47D. Co-IP of ER (bait, red, Santa Cruz:sc-8002) identified GRHL2 (green, Atlas:
HPA004820) as an interactor in estrogenic conditions (M = marker, I = input, FT = flow through, IP = immunoprecipitation). siRNA knockdown of
GRHL2 in MCF7 (right) resulted in a loss of the ~ 75-kDa band
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is not a challenge as projects like the TCGA provide
transcriptome-wide data for a range of cancers. It is
therefore only in the cases of rarer disease types
(such as neuroendocrine tumor) and orphan tissues
that this limitation will be problematic as these are
poorly represented in public data. Even so, in these
cases where specific networks cannot be generated,
pan-tissue regulatory networks are currently being de-
veloped to overcome this limitation and these could
be adapted for VULCAN [45].
Fig. 8 Effect of GRHL2 knockdown after 24 h on eRNA at E2-responsive binding sites and overexpression of GRHL2 Δ425–437. (a) Overexpression
of GRHL2 in MCF7 resulted in a reduction of eRNA transcribed from the GREB1, TFF1, and XBP1 enhancers. The effect was significant at TFF1 and
XBP1 enhancers (p < 0.05, paired t test). (b) Overexpression of GRHL2 Δ425–437 (delta) compared to empty vector (EV) and GRHL2 wild type (OE)
at 24 h. In all three cell lines at all three loci, overexpression of the wild type (WT) led to a reduction in the mean eRNA production at GREB1,
TFF1, and XPB1. This effect was significant in six out of nine experiments (p < 0.05, t test, one-tailed, paired). Overexpression of GRHL2 Δ425–437
had a reduced effect that led to a significant reduction in only two out of nine experiments (p < 0.05, t test, one-tailed, paired). Importantly, in
four out of nine experiments, WT overexpression had significantly less eRNA production than GRHL2 Δ425–437, suggesting the P300 inhibition
domain plays a role in the regulation of eRNA production
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By developing VULCAN, we have been able to redis-
cover the known cofactors of the estradiol-responsive
ER complex and predict and experimentally validate a
novel protein-protein interaction.
GRHL2-ER interaction
GRHL2 has a key role in regulating EMT
In the 4T1 tumor model, GRHL2 was found to be sig-
nificantly downregulated in cells that had undergone
A
B
C
Fig. 9 Changes in H3K27ac on knockdown of GRHL2. (a) The effect of silencing GRHL2 on H3K27ac at 48 h in MCF7 and T47D cell lines was
monitored by ChIP-seq. Analysis of sites proximal to TFF1, XBP1, and GREB1 showed significant changes in acetylation at all three sites in MCF7.
Significant changes were only found at GREB1 in T47D (top right). While XBP1 and GREB1 show an increase in histone acetylation on silencing
GRHL2, TFF1 showed the reverse effect. (b) Genome-wide, the effects of silencing GRHL2 led to a significant redistribution of H3K27ac in both the
MCF7 and T47D cell lines, with both showing an increase and decrease in the histone mark dependent on site. c From left to right. Coverage as
calculated by Homer. H3K27ac was found at GRHL2 sites in both MCF7 and T47D cells, in particular at the E2-responsive sites. The same mark was
also found at P300 sites as expected. Analysis of ER binding at H3K27ac sites showed an enrichment for ER binding at the H3K27ac sites that
were most responsive to knockdown of GRHL2 in MCF7 cells
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EMT [28]. The same study showed that knockdown of
GRHL2 in MCF10A—an ER-negative cell line—led to
the loss of epithelial morphology. Overall, this suggested
that the GRHL2 transcription factor plays an essential
role in maintaining the epithelial phenotype of breast
cells. Similar results were observed with the
MDA-MB-231 model, where expression of GRHL2 re-
sulted in the reversal of EMT [29]. This result has been
recapitulated in hepatocytes, where GRHL2 was found
to suppress EMT by inhibiting P300 [43]. The ability to
suppress EMT has also been noted in prostate cancer,
another cancer driven by a steroid hormone receptor
(AR), and the genes regulated by GRHL2 are linked to
disease progression [46].
GRHL2, a novel co-repressor of ER eRNA production
These earlier data combined with the link between
GRHL2 expression and patient survival indicate a sig-
nificant role for GRHL2 in the progression of breast
cancer. However, its role in the ER signaling axis has,
until now, been unknown. Here, we show that GRHL2
performs its activity at a subset of ER enhancers. Over-
expression of GRHL2 resulted in a significant decrease
in eRNA production at the TFF1 and XBP1 enhancers,
and in agreement with previous studies that correlate
eRNA transcription with gene expression [47–49], we
found the measured eRNA decrease was concurrent
with a significant downregulation in the expression of
the corresponding gene.
These results are consistent with previous findings
that GRHL2 inhibits P300 [43] and, while the ER com-
plex results in the activation of eRNA transcription at
these sites, that GRHL2 plays a role in fine-tuning or
modulating this process.
GRHL2 role in the ER signaling axis is independent to its
role in tethering MLL3
In breast cancer, GRHL2 has previously been shown to
directly interact with FOXA1, which may contribute to
the tethering of the histone methyltransferase MLL3
and, consequently, epigenetic marks at GRHL2/FOXA1
binding sites [30]. Our analysis, however, showed no
particular enrichment for H3K4me1/3 marks at
E2-responsive GRHL2 sites compared to other GRHL2
binding sites, and our proteomic analysis of interactors
showed a strong association with proteins related to
transcription. We proposed that these ER-responsive
sites are related to the role of GRHL2 in a transcrip-
tional process independent of its interaction with MLL3.
This was supported by evidence of a significant overlap
with binding of the coactivator P300, transcriptional
proteins detected by qPLEX-RIME analysis of GR, and a
pronounced increase in eRNA transcription at
E2-responsive GRHL2 sites.
ER is bound more strongly at active enhancers (H3K27ac)
that are altered by siGRHL2
Knockdown of GRHL2 led to a genome-wide remodel-
ing of H3K27ac marks, found at active enhancers, con-
firming a role of GRHL2 in partially regulating these
sites. Detailed inspection of the data showed a significant
increase of these marks around the XBP1 and GREB1
genes, supporting our hypothesis that GRHL2 has a par-
tial inhibitory role within the ER regulon. The result was
further supported by finding enrichment of ER binding
events at H3K27ac marks altered by GRHL2 knockdown
(Fig. 9c, right panel). The more complex effect on
H3K12ac, when compared to the effects on eRNA pro-
duction, is likely a result of the diversity of roles that
GRHL2 holds within the cell, leading to a host of down-
stream effects in the regulation of chromatin recruit-
ment of key factors such as MLL3, ER, and FOXA1[30].
Deletion of the P300 inhibitory α-helix from GRHL2 reduces
the protein’s ability to repress the production of eRNA at ER
bound enhancer sites
Finally, to clarify if inhibition of P300 was occurring, we
generated and overexpressed GRHL2 lacking the inhibi-
tory alpha helix between amino acids 425 and 437. In all
cases, GRHL2 Δ425–437 had reduced an inhibitory ef-
fect compared to overexpression of the wild type, con-
firming that GRHL2 primarily plays a repressive role at
these sites.
Conclusion
VULCAN is built on state-of-the-art network analysis
tools previously applied to RNA-seq data. By adapting
network-based strategies to ChIP-seq data, we have been
able to reveal novel information regarding the regulation
of breast cancer in a model system.
We have demonstrated that the VULCAN algorithm
can be applied generally to ChIP-seq for the identifica-
tion of new key regulator interactions. Our method pro-
vides a novel approach to investigate chromatin
occupancy of cofactors that are too transient or for
which no reliable antibody is available for direct
ChIP-seq analysis.
Further, because of our use of clinical data, VULCAN
results are both more likely to be relevant and are spe-
cific to the disease type studied, as demonstrated in the
loss of signal when using a control co-expression net-
work generated from an alternative disease type.
VULCAN enabled us to identify the GRHL2-ER inter-
action and that GRHL2 plays a repressive role. Further
analysis showed the process to be independent of the
previously reported interaction with FOXA1 and MLL3
[30]. Our conclusion, therefore, is that GRHL2 has a
second, previously undescribed role that regulates
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transcription at specific estrogen-responsive enhancers
(Fig. 10).
Given the central role of the ER in breast cancer devel-
opment and GRHL2’s own ability to regulate EMT, the
discovery that ER recruits GRHL2 leading to the altered
eRNA production is an important step in enhancing our
understanding of breast cancer and tumorigenesis.
Methods
VULCAN
An implementation of VULCAN in R is available on
Bioconductor.org [https://bioconductor.org/packages/re-
lease/bioc/html/vulcan.html], and the scripts to replicate
our analysis are available as Rmarkdown files. Unless
otherwise specified, all p values were Bonferroni
corrected.
Sample preparation
MCF7 cells were obtained from the CRUK Cambridge
Institute collection, authenticated by STR genotyping
and confirmed free of mycoplasma. All cells were main-
tained at 37 °C, 5% CO2. For each individual ChIP pull-
down, we cultured 8 × 107 MCF7 cells (ATCC) across
four 15-cm-diameter plates in DMEM with 10% FBS,
glutamine and penicillin/streptomycin (Glibco). Five
days before the experiment, the cells were washed with
phosphate-buffered saline (PBS) and the media were re-
placed with clear DMEM supplemented with
charcoal-treated serum. The media was refreshed every
24 h, which halted the growth of the cells and ensured
that majority ER within the cell was not active. On day
5, the cells were treated with estradiol (100 nM). At the
appropriate time point, the cells were washed with
ice-cold PBS twice and then fixed by incubating with 10
mL per plate of 1% formaldehyde in unsupplemented
clear media for 10 min. The reaction was stopped by the
addition of 1.5 mL of 2.5M glycine, and the plates were
washed twice with ice-cold PBS. Each plate was then
scraped in 1 mL of PBS with protease inhibitors (PI) into
a 1.5-mL microcentrifuge tube. The cells were centri-
fuged at 8000 rpm for 3 min at 4 °C and the supernatant
removed. The process was repeated for a second wash in
1 mL PBS+PI and the PBS removed before storing at −
80 °C.
ChIP-seq
Frozen samples were processed using established ChIP
protocols [50] to obtain DNA fragments of ~ 300 bp in
Fig. 10 Overview of the role of GRHL2 in ER activation. On activation of the ER by the ligand E2, the protein is released from a complex containing
HSPs and translocates to the nucleus. The holo-ER dimer forms a core complex at estrogen response elements (ERE) with FOXA1 (pioneer factor) and
GATA3. ER further recruits P300 and GRHL2. GRHL2 has an inhibitory effect on P300 (a transcriptional activator interacting with TFIID, TFIIB, and RNAPII),
thereby reducing the level of eRNA transcription at enhancer sites. Overexpression of GRHL2 further suppresses transcription, while knockdown of
GRHL2 reverses the process
Holding et al. Genome Biology           (2019) 20:91 Page 13 of 16
length. The libraries were prepared from the purified
DNA using a ThruPLEX DNA-seq kit (Rubicon Genom-
ics) and sequenced on the Illumina HiSeq Platform. Se-
quencing data is available from Gene Expression
Omnibus, accession GSE109820 and GSE123475.
Differential binding analysis
Sequencing data was aligned using BWA [51] to the hu-
man genome (hg19). Reads from within the DAC Black-
listed Regions was removed before peak calling with
MACS 2.1 [52] on default parameters. The aligned reads
and associated peak files were then analyzed using Diff-
Bind [18] to identify significant changes in ER binding.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed as
described by Subramanian et al. [53] using the curated
pathway collection (C2) from MSIGDB v 5.0 with 1000
set permutations for each pathway investigated, followed
by Benjamini-Hochberg p value correction.
Motif analysis
Motif analysis of the binding regions was undertaken
with Homer v4.4 [54] using default parameters.
Motif logo rendering was performed using Weblogo
v2.8.2 [55].
VULCAN analysis
We reconstructed a regulatory gene network using
ARACNe-AP as described by Alvarez [56]. RNA-seq
breast cancer data was downloaded from TCGA in Janu-
ary 2015 and VST-Normalized as described by Anders
and Huber [57]. The ARACNe transcriptional regulation
network was imported into R using the VIPER BioCon-
ductor package, and it was interrogated using the differ-
ential binding profiles from our ChIP-seq experiment as
signatures, 45 min vs control and 90 min vs control. The
peak-to-promoter assignment was performed using a
10-kb window with respect to the transcription starting
site (TSS) of every gene on the hg19 human genome.
The algorithm msVIPER (multi-sample Virtual Inference
of Protein activity by Enriched Regulon analysis) was
then applied, leveraging the full set of 8 replicates per
group, with 1000 signature permutations and default
parameters.
qPLEX-RIME
Samples were prepared as previously described for RIME
[9]; the protocol was modified to include TMT isobaric
labels for quantification [33].
TF binding overlap
Publicly available data was downloaded as described in
the source publication [3, 30, 34, 35], and overlap was
calculated with bedtools (v2.25.0). Presented data was
normalized as a percentage of GRHL2 sites.
eRNA quantification
MCF7 cells were transfected with Smart Pool siRNA
(Dharmacon, L-014515-02), siControl, GRHL2 overex-
pression vector (Origene, RC214498), GRHL2 Δ425–437
(Origene), or empty control vector using Lipofectamine
3000 (Thermo Fisher Scientific) according to the manu-
facturer’s protocol in 6-well format. Expression was
monitored by rtPCR using TaqMan assay with GAPDH
as a control transcript. Knockdown efficiency was ~ 75%,
and the GRHL2 overexpression vector led a 730-fold in-
crease in expression over control plasmid. One micro-
gram of purified RNA was reverse transcribed with
Superscript III reverse transcriptase (Thermo Fisher Sci-
entific, 18080085) using random primers (Promega,
C1181) according to the manufacturer’s instructions.
eRNAs were quantified with qPCR using Power SYBR™
Green PCR Master Mix (Thermo Fisher Scientific,
4367660) and denoted as relative eRNA levels after nor-
malizing with UBC mRNA levels.
Primer name Sequences Reference
eGREB1 F ACTGCGGCATTTCTGTGAGA This study
eGREB1 R ACTGCAGTTTGCCTGTCACT This study
eXBP1 F TGTGAGCACTTGGCATCCAT Nagarajan et al. [58]
eXBP1 R ACAGGGCCTCATTCTCCTCT Nagarajan et al. [58]
eTFF1 F AGGGGATGTGTGTGAGAAGG Li et al. [59]
eTFF1 R GCTTCGAGACAGTGGGAGTC Li et al. [59]
UBC F ATTTGGGTCGCGGTTCTTG Peña et al. [60]
UBC R TGCCTTGACATTCTCGATGGT Peña et al. [60]
Co-immunoprecipitation
ERα (F10) antibody, Santa Cruz (sc-8002), was cleaned
using Amicon 10K Buffer Exchange Column (EMD, Cat
# UFC501096) to remove the sodium azide. 2.5 μg ERα
(F10) antibody rotated overnight at 4 °C with 100 μL
Dynabeads Protein A, Invitrogen (10001D).
Nuclear lysate was harvested via cell lysis (20 mM
Tris-HCl, 20 mM NaCl, 0.2 mM EDTA) followed by nu-
clear lysis (20 mM Tris-HCl, 20 mM NaCl, 0.2 mM
EDTA 1% IGEPAL). The uclear lysate was then incu-
bated overnight at 4 °C with the Dynabeads Protein A.
Elution via 10 min incubation at 70 °C with 1× NuPAGE
LDS Sample Buffer, Invitrogen (NP0007), and 1×
NuPAGE Sample Reducing Agent, Invitrogen (NP0004),
and subjected to western blotting.
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Knockdown of GRHL2
Knockdown of GRHL2 was undertaken using
ON-TARGETplus SMARTpool Human GRHL2, Dharma-
con (#L-014515-02-0050) and Lipofectamine® RNAiMAX
Reagent Protocol (Thermo) according to the manufac-
turer’s protocol. Control samples were prepared following
the same method using ON-TARGETplus Control pool
Non-targeting pool, Dharmacon (#D-001810-10-50) in
place of siGRHL2.
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